American College of Cardiology3d
BRAIN-AF: Rivaroxaban Did Not Reduce Cognitive Decline, Stroke and TIA in Younger, Low-Risk Patients With AFib
Rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack (TIA) in patients younger than 65 with nonvalvular atrial fibrillation (AFib) and low risk for stroke ...
American College of Cardiology3d
OPTION: LAAC vs. Oral Anticoagulation in High-Risk Patients Undergoing AFib Ablation
Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared ...
American College of Cardiology4d
Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation - BRAIN-AF
The BRAIN-AF trial failed to show that rivaroxaban prevents cognitive decline, stroke, or TIA among patients with AF. The primary outcome, cognitive decline (defined by a ≥2-point reduction in ...
American College of Cardiology3d
Late-Breaking Science Explores AI and Other Innovations Designed to Improve Heart Health
A late-breaking session at AHA 2024 highlighted new research focusing on "Smart Cardiology" innovations, including artificial intelligence (AI), aimed at improving heart health. In the PHARM-HF A&F ...
American College of Cardiology3d
VANISH2: Catheter Ablation vs. AAD as First-Line Strategy
Among patients with ischemic cardiomyopathy and ventricular tachycardia (VT), catheter ablation as a first-line strategy over antiarrhythmic drugs (AAD) was associated with a lower risk of the primary ...
American College of Cardiology3d
Comparison of Anticoagulation With Left Atrial Appendage Closure After Atrial Fibrillation Ablation - OPTION
The OPTION trial showed that left atrial appendage closure after AF ablation was associated with a lower risk of non–procedure-related major or clinically relevant nonmajor bleeding compared with oral ...
American College of Cardiology5d
Diagnosis and Management of Kawasaki Disease: Key Points
The following are key points to remember from an American Heart Association scientific statement on the diagnosis and management of Kawasaki disease: ...
American College of Cardiology3d
SUMMIT: Tirzepatide Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, ...
American College of Cardiology6d
Transseptal Mitral Valve-in-Valve Procedure, Complete vs. Culprit-Only Revascularization in Older Patients, Hypertensive Pregnancy and MI Risk
In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs ...
American College of Cardiology4d
Ventricular Tachycardia Antiarrhythmics or Ablation in Structural Heart Disease 2 - VANISH2
The VANISH2 trial showed that in patients with ischemic cardiomyopathy and VT, first-line therapy with catheter ablation resulted in fewer VT episodes requiring ICD shock or medical intervention ...
American College of Cardiology7d
Independence of Lp(a) and LDL-C–Mediated CV Risk
Bhatia HS, Wandel S, Willeit P, et al. A participant-level meta-analysis of 27,658 participants enrolled in six placebo-controlled statin trials was performed to assess the association of LDL-C and Lp ...
American College of Cardiology7d
M-TEER for Secondary MR With Preserved LVEF
Huded CP, Chhatriwalla AK, Shah MA, Vemulapalli S, Kosinski A, Cohen DJ. This retrospective cohort study reports that in patients with secondary MR and preserved LVEF, M-TEER was associated with a ...